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Background: About a third of the global HIV infections outside sub-Saharan Africa are related to injecting drug use
(IDU), and this accounts for a growing proportion of persons living with HIV. This paper is a response to the need
to monitor the state of the HIV epidemic as it relates to IDU and the availability of HIV treatment and harm
reduction services in 21 high epidemic countries.
Methods: A data collection form was designed to cover questions on rates of IDU, prevalence and incidence of HIV
and information on HIV treatment and harm reduction services available to people who inject drugs (PWID).
National and regional data on HIV infection, IDU in the form of reports and journal articles were sought from key
informants in conjunction with a systematic search of the literature.
Results: Completed data collection forms were received for 11 countries. Additional country-specific information
was sourced via the literature search. The overall proportion of HIV positive PWID in the selected countries ranged
from 3% in Kazakhstan to 58% in Vietnam. While IDU is relatively rare in sub-Saharan Africa, it is the main driver of
HIV in Mauritius and Kenya, with roughly 47% and 36% of PWID respectively being HIV positive. All countries had
antiretroviral treatment (ART) available to PWID, but data on service coverage were mainly missing. By the end of
2010, uptake of needle and syringe programmes (NSP) in Bangladesh, India and Slovakia reached the internationally
recommended target of 200 syringes per person, while uptake in Kazakhstan, Vietnam and Tajikistan reached
between 100-200 syringes per person. The proportion of PWID receiving opioid substitution therapy (OST) ranged
from 0.1% in Kazakhstan to 32.8% in Mauritius, with coverage of less than 3% for most countries.
Conclusions: In order to be able to monitor the impact of HIV treatment and harm reduction services for PWID on
the epidemic, epidemiological data on IDU and harm reduction service provision to PWID needs to be regularly
collected using standardised indicators.
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Globally there are approximately 15.9 million people
who inject drugs (PWID), with around 80% of PWID liv-
ing in low and middle income countries (LMIC) [1]. The
continued high prevalence of injection drug use (IDU) is
cause for concern because of the strong association be-
tween IDU and risk for Human Immunodeficiency Virus* Correspondence: zaino.petersen@mrc.ac.za
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reproduction in any medium, provided the or(HIV) transmission. This association is largely due to the
sharing of drug paraphernalia with other PWID, with
needle sharing accounting for about one tenth of new
HIV infections globally and almost a third of all new HIV
infections outside sub-Saharan Africa [2]. Regions with
particularly high rates of new HIV infections among
PWID include Eastern Europe and Central Asia as well as
East and South-East Asia [3].
In contrast, there has been a decline in HIV incidence
in the USA and Western Europe [4]. This decline has been
spurred on by behaviour changes among at-risk populations
(including PWID) as well as improved access to HIVl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions [5-7]. However, access to adequate HIV treatment
and harm reduction services for PWID varies from country
to country. Earlier work has shown that many of the coun-
tries with high rates of new HIV infections among PWID
fail to provide PWID with access to the recommended
comprehensive package of evidence-based HIV treatment
and harm reduction services [8,9]. In particular, limited
availability of antiretroviral therapy (ART) and harm reduc-
tion services (such as needle and syringe programmes
(NSP) and opioid substitution therapy (OST)) is a major
barrier to efforts to limit HIV transmission amongst PWID
and their injecting and sexual partners [10-12].
Even in countries that report the availability of core
HIV treatment and harm reduction services for PWID,
earlier work has highlighted that ART, NSP and OST
service coverage is generally below the minimum thresh-
old needed to adequately prevent new HIV infections
among PWID [12-14]. Concerns about the poor availabil-
ity and limited coverage of these services have led to con-
tinued calls for the introduction of and, where present,
scaling up of the provision of these services. Although
these services are especially important for countries where
the HIV epidemic is concentrated amongst PWID, they
are also vital for countries where IDU is an emerging pub-
lic health concern [11-13]. In order to guide effective
country-level responses to these issues, updated informa-
tion is needed on IDU rates, prevalence of HIV among
PWID, the types of treatment and harm reduction services
provided to PWID living with HIV and the degree of ser-
vice coverage. Although global reviews of the epidemi-
ology of HIV among PWID [2] and HIV service coverage
[12] have been conducted in the past five years, several
LMICs with emerging HIV epidemics among PWID have
not had data available to contribute to these reviews. For
other high epidemic countries, it is unclear whether the
prevalence of HIV and the extent to which HIV treatment
and harm reduction services are available for PWID have
changed since the time of the last review [2].
This paper is in response to this need for updated data
on HIV prevalence and harm reduction service provision
among PWID for 21 LMICs with either high or emerging
HIV epidemics among PWID. More specifically, this paper
describes the (i) prevalence of IDU; (ii) the prevalence of
HIV among PWID; (iii) the provision of NSP, OST and
ART to PWID; and (iv) the extent to which NSP, OST and
ART are provided relative to the size of the IDU popula-
tion in the 21 selected countries.
Methods
Sample description
Twenty-one countries were chosen by the Steering
Committee of the International Reference Group to the
United Nations on IDU and HIV to participate in thisstudy. These countries were selected based on the state
of the HIV epidemic in these countries, resource needs
and availability of partner organizations to support ef-
forts to introduce and/or scale up HIV treatment and
harm reduction services. Selected countries included:
Afghanistan, Bangladesh, Belarus, China, India, Indonesia,
Kenya, Kazakhstan, Kyrgyzstan, Lithuania, Mauritius,
Moldova, Myanmar, Nepal, Nigeria, Pakistan, Russia,
South Africa, Tanzania, Ukraine and Vietnam.Data collection
A data collection form was used to collect national and re-
gional estimates of the population prevalence of IDU,
prevalence of HIV, availability and coverage of HIV treat-
ment (the provision of ART) and harm reduction services
for PWID (the provision of NSP/OST in the 21 countries
between June 2010 and June 2011). These forms were
completed by key contacts who were experts in IDU and
HIV in the selected countries. The forms were also used
by the research team to guide data extraction from
country reports and relevant publications. The content of
this data collection form was informed by the Steering
Committee of the Reference Group, the Secretariat to the
UN Reference Group and prior data collection exercises
conducted by the Reference Group [2,11]. In addition, key
contacts were asked to provide supporting evidence in the
form of reports, publications and presentations where
these were available. After only receiving completed data
collection forms from 11 of the 21 countries and realizing
that recent 2010-2011 information on these key indicators
was not yet available for many of the selected countries,
we undertook a literature search using Sciencedirect,
PubMed, Google, and Google scholar and Ebscohost. The
websites of international agencies with a presence in these
countries (e.g. UNODC, UNAIDS and WHO), and the
conference proceedings of recent international meetings
on HIV and drug use to identify recent reports and
publications on the epidemiology of IDU and HIV in the
selected 21 countries. This information was searched for
between January 2011 and January 2012, and only the
most updated information (from 2010 and later) was in-
cluded. Literature was further sifted according to whether
it contained information on the 21 selected countries and
whether it described the main prompts on the data collec-
tion form (IDU and HIV prevalence, as well as OST, NSP
and ART availability). Data were extracted from these
reports, presentations and publications using the afore-
mentioned data collection form. Information from the
literature was checked by three staff members, with one
member doing the search, and two others cross checking
and updating information where necessary. Reference
group members in the diferent countries were alo given
the opportunity to update findings.
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Prevalence of IDU and HIV among PWID
Of the 21 participating countries, the Russian Federation
and the Ukraine were countries identified with the highest
rates of reported IDU, with roughly 2 million (2% of adult
the population) and 425000 (1.3% of the adult population)
injecting drugs respectively (Table 1). In the selected coun-
tries, the overall proportion of PWID living with HIV
ranged from 3% in Kazakhstan to 58% in Vietnam (Table 1).
Taking the midpoint in cases where a range was given, the
average proportion of PWID living with HIV across the 19
countries where data were available was almost 22%. How-
ever country-level estimates sometimes mask regional
concentrations of HIV among PWID. For example, a re-
cent UNAIDS publication reported HIV prevalence in
St Petersburg, Russia, to have doubled in the past five
years, with approximately 60% of PWID in this city living
with HIV [6].
HIV prevalence among PWID in one region of
Afghanistan was found to have increased from 3% in
2006 to 7% by 2011 (Table 1). While pilot harm reduc-
tion programmes are available (NSP’s and drug rehabil-
itation centres), a scale-up of these interventions is
urgently required for IDU’s in order to prevent a futureTable 1 Estimated population size, proportion of population th
Country Population (all ages) Population (15-64 years) No of PW
Afghanistan 29,835,392 16,492,454 19
Bangladesh 158,570,535 96.847,950 20
Belarus 9,557,552 6,870,907 69
China 1,336,718,015 983,280,460
India 1,210,193,422 771,476,660 177,
Indonesia 237.6 million 163,367,691
Kenya 41,070,934 22,634,399
Kazakhstan 16,455,000 11,028,216
Kyrgyzstan 5,587,443 3,656,055
Lithuania 3.2 million 2,475,902
Mauritius 1,286,340 921,618
Moldova 4,314,377 3,193,494
Myanmar 53,999,804 36,442,403
Nepal 29,391,883 17,951,875
Nigeria 155,215,573 86,830,770
Pakistan 187,342,721 113,072,889
Russia 142,905,208 99,594,130
South Africa 49,054,031 32,259,360
Tanzania 42,746,620 23,547,672 25
Ukraine 45,134,707 31,956,390 325
Vietnam 90,549,390 62,721,185
1 calculated from a national 2008 Survey.
*An estimation of the number of PWID that were HIV positive by 2010. Where upda
periods 2006-2010. **Calculated at the midpoint of the range where applicable. ___HIV epidemic [15,16]. Whilst Bangladesh experienced
an increase in the rates of HIV between 2001 and 2009,
one area (Dhaka) where harm reduction programmes
are available experienced a decrease in the rates of new
HIV infections. Here the availability of harm reduction
programmes for PWID resulted in a reduction in HIV
prevalence from 7% in 2007 to 5.3% in 2011 [6];
(Table 1).
While IDU is relatively rare in sub-Saharan Africa,
IDU appears to act as the main driver of HIV in
Mauritius, with roughly 47% of PWID being HIV posi-
tive. Other available research in sub-Saharan Africa
shows a high HIV prevalence among PWID in Kenya
(36%), Zanzibar in Tanzania (26%), and the Kano region
in Nigeria (10%) [5]; (Table 1).
Availability of core HIV treatment (ART) and harm
reduction (NSP/OST) services for PWID
All 21 countries reported that ART was available to
PWID living with HIV (Table 2). However, most coun-
tries collected data on the number of services providing
ART to the general public rather than the number of
services providing ART to PWID specifically. Of concern
is the large number of countries with high prevalenceat inject drug and the number of HIV-positive drug users*
ID1 (range) No. of PWID that are HIV+* (range) % of HIV+ PWID**
,000-25,000 1,330-1,750 7
,000-40,000 1,600-3,200 8
,200-83,400 9,480-11,425 13.7
642,000 44,940-83,460 7-13
000-180,000 16,284-16,560 9.2
222,500 60,075 27
30,000 10,800-12,900 36-43
186,000 5,580 3
_______ _______ _______
5,458 1,250 22.9
10,000 4,740 47.4
25,000 4,450 17.8
75,000 27,750-28,500 37-38
28,500 5,415 19
________ _______ 8.918
125,000 26,250 21
2 million _______ _______
67,0001 12,998 19.4
,000-50,000 10,500-21,000 42
000-425000 74,425-97,325 22.9
142,000 45,440-82,360 32-58
ted data was not available the latest reported prevalence was used, including
___ Data is not available.
Table 2 Availability and coverage of ART among PWID in 2010-
Country ART availability 2011 Est. no. of HIV positivepop receiving ART3
No. of HIV+ PWID Est. no. of HIV+ PWID
receiving ART
Afghanistan yes ——————— 1330-1750 12
Bangladesh yes 1725 1600-32005 353 (Dec 09)
Belarus yes 2,614 _______ _______
China yes 86,122 169120-314080 12 762
India yes 424,802 16284-16560 1900
Indonesia yes 19,572 _______ _______
Kenya yes 432,621* 10800-12900 _______
Kazakhstan yes 1,336 5208 182
Kyrgyzstan yes 548 _______ 115
Lithuania yes _______ 1250 62
Mauritius yes 646 4740 530
Moldova yes 1,237 4450 446
Myanmar yes 29,825 27750-28500 _______
Nepal yes 4,867 8% _______
Nigeria yes 359,181P 8.9%18 _______
Pakistan yes 1,892 26,250 _______
Russia yes 79,430 ________ _______
South Africa yes 1,389,865* 1920 _______
Tanzania yes 258,069 10500-21000 Unknown
Ukraine yes 22,697 74425-97325 1732 (Jan 2011
Vietnam yes 49,492 45440-82360 _______
* Estimated no of “general population” receiving ART.
______ Data are not available.
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tion of HIV-positive PWID receiving ART. Even where
data were available, the estimated proportion of PWID
living with HIV and using ART was low, ranging from
0.6% in Afghanistan to 22% in Bangladesh.
In terms of the availability of HIV prevention services
for PWID, in 2011 NSPs were available in 20 of the 21
countries examined, but the number of NSP sites varied
per country (Table 3). In countries where rates of IDU
were low (such as South Africa) introducing NSPs is
often not publicly accepted. For example one NSP site has
been established in South Africa, however this service is
affiliated to an organization providing services to men
who have sex with men (MSM), which indicates limited
reach to PWID who are not MSM. While Mauritius has
some NSPs and Tanzania has pilot programmes, these ser-
vices are unavailable in Kenya and Nigeria (Table 3).
In addition, information on the degree of service cover-
age provided by available NSPs (in terms of the total num-
ber of needles distributed per annum and the number of
needles provided to each PWID) was unavailable for 9 of
the 21 countries (Table 3). For the 13 countries with avail-
able data on the number of needles distributed per year,
most countries (10) reported low levels of NSP coverage(Table 3). In other words, they provide fewer than 100
needles and syringes per PWID per year [17]. However
by the end of 2010, NSP coverage in two countries
(Bangladesh and India) had reached the internationally
recommended target of 200 syringes per PWID with
coverage in Kazakhstan and Vietnam having reached
medium levels; that is between 100-200 syringes per
PWID per year [18].
OST as treatment for opioid dependence and as a means
of reducing risky injection practices was available in 17 of
the 21 selected countries (Table 4). Of the countries that
provided OST, methadone maintenance therapy (MMT)
was recorded as the most widely used treatment modality.
Information on OST provision was not available for
six of the 21 countries (Afghanistan, Belarus, Indonesia,
Kenya, Kyrgyzstan, and Vietnam). Two countries (Russia
and Pakistan) reporting no OST service provision, and
with either MMT or buprenorphine maintenance ther-
apy (BMT) available in 13 countries (Table 4). Further-
more, OST service coverage is generally poor in most of
the countries reporting OST sites, with less than 3% of
PWID in 11 of the 21 countries with available data. For
example, South Africa has had BMT available for a few
years in the private sector and recently MMT has also
Table 3 Availability and coverage of needle and syringe programs (NSP) in 2010-11
Country
NSP availability No. of NSP
sites nationally
No. of PWID served
in last 12 months
No. of syringes per
PWID distributed in
1 year (Jan-Dec 2010)
Afghanistan yes 9 _______ 34.7
Bangladesh yes 120 26000 214.4
Belarus yes _______ _______ 46.5
China yes 1052 39,500 18.9
India yes 261 135000 228.2
Indonesia yes _______ _______ 10.2
Kenya no _______ _______ _______
Kazakhstan yes 168 73,252 176.4
Kyrgyzstan yes _______ _______ _______
Lithuania yes 12 429 _______
Mauritius yes 52 6000 p/y 51.9
Moldova yes 29 _______ 65.8
Myanmar Yes 40 (2008) 13368 91.7
Nepal Yes 9 _______ 56.5
Nigeria No _______ _______ _______
Pakistan Yes 15 1500 _______
Russia Yes 69 _______ _______
South
Africa
Yes 1 _______ _______
Tanzania Yes 1 (new , Jul2011) 1048 _______
Ukraine Yes 1633 174796 62.4
Vietnam Yes _______ _______ 140.6
______ Data are not available.
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no public OST sites available. More specifically, the pro-
portion of PWID receiving OST ranges from 0.1% in
Kazakhstan to 32.8% in Mauritius. In addition, two
countries (Bangladesh and Tanzania) have only recently
started providing OST, with one pilot site available in
each country.
Discussion
This paper details the prevalence of IDU and HIV, the
availability of HIV treatment (ART) and harm reduction
(NSP/OST) services across 21 countries with either high
or emerging HIV epidemics among PWID, and efforts to
scale up service coverage to PWID. The increasing rates
of IDU and HIV among IDU remain concerning. Varying
rates of HIV prevalence among PWID and varying levels
of HIV treatment and harm reduction service coverage
have been noted.
First, this study found that countries surveyed vary with
regards to IDU trends, with some having a very high
prevalence of IDU, while it is an emerging trend in others.
Specifically, across the 21 countries surveyed, the Russian
Federation and the Ukraine are the countries with thehighest prevalence of IDU, while most African countries
have comparatively lower proportions of PWID. Despite
this, IDU is a cause for concern in African countries,
which already have generalized HIV epidemics. Failure to
address IDU and HIV risk among PWID in this region
will impact negatively on efforts to prevent new HIV in-
fections and curtail the epidemic. Between one fifth and a
quarter of PWID across the selected countries are living
with HIV. The average proportion of PWID who are HIV
positive is just under 22% across the 19 countries where
data were available.
Second, the paper also highlights the poor coverage of
ART services for PWID, across the 21 countries. The
proportion of PWID who are HIV positive and who re-
ceive ART is very low (less than 12% with the exception of
Bangladesh). This could be because they are still healthy
(CD4 counts that are still high), however, this information
is lacking and in light of recent reports [19], it is more
likely that it is because of barriers to accessing ART for
PWID. The lack of updated data with regards to IDU and
HIV services to PWID is a matter of concern for many of
the 21 countries. A large number of countries with high
prevalence rates of HIV among PWID are not aware of
Table 4 Availability and coverage of opioid substitution therapy (OST) 2010-11
Country OST availability No. of OST
sites nationally
MMT/BMT % of PWID receiving OST
in last 12 months, Dec 2010
Afghanistan Yes _______ _______ 0.4
Bangladesh Yes 1 MMT 0.3
Belarus Yes _______ _______ 0.9
China Yes 928 MMT 28.4
India Yes 65 BMT 3
Indonesia Yes 9 _______ 2.4
Kenya _______ _______ _______ _______
Kazakhstan Yes 10 MMT 0.1
Kyrgyzstan _______ _______ _______ _______
Lithuania Yes 21 MMT&BMT _______
Mauritius Yes 16 MMT 32.8
Moldova Yes 8 MMT 1.4
Myanmar Yes 10 MMT 1.5
Nepal yes 8 _______ 1.2
Nigeria yes _______ _______ _______
Pakistan No _______ _______ _______
Russia No _______ _______ _______
South Africa Yes _______ BMT&MMT _______
Tanzania Yes 1 new Feb 2011 MMT 0.7
Ukraine Yes 125 MMT and BMT 2.1
Vietnam Yes 8 _______ 1.3
_______Data are not available.
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ART. This is a major concern as ART use can help de-
crease risk of transmission among PWID and also their sex-
ual partners. Data on ART service coverage disaggregated
by IDU is increasingly necessary, especially in countries
with a high prevalence of HIV among IDU, but also for
countries where IDU is an emerging problem. This data
could serve as a baseline for informing the development,
implementation and scaling up of HIV treatment services
for PWID.
Third, we noted that these 21 countries also vary in the
extent to which they provide harm reduction services to
PWID, with some countries having established harm reduc-
tion services for PWID, and others only beginning to pilot
harm reduction programs, due to the rising prevalence of
IDU. NSP, in particular, is a fairly new phenomenon in
many of the selected countries, with some countries only
having one or two pilot NSP sites to date. While most of
the selected countries now have NSP available, the extent
to which PWID have access to such programmes is ques-
tionable. In countries where NSPs are available, only two
out of the 21 countries (Kazakhstan and Vietnam) provided
medium coverage (between 100-200 syringes per IDU per
year), and only two countries provided high coverage
(Bangladesh and India). These findings suggest that muchmore needs to be done to bring these NSPs to scale and
help prevent new HIV infections. Barriers to the provision
of clean syringes to PWID and uptake of services also need
to be addressed in order to improve harm reduction
practices.
While many of the selected countries had OST available
to PWID, the number of sites per country was low with
very few PWID having access to such services. While not
all PWID (particularly those injecting amphetamine type
stimulants (ATS) require OST, OST coverage still appears
to be low (less than 3%) although some exceptions were
noted, namely China and Mauritius. A recent report also
noted the emergence of amphetamine type stimulants
(ATS) in many countries, and the need for harm reduction
services for people who inject ATS [20]. This report high-
lights the lack of information on ATS, as most of the
countries do not routinely differentiate between amphet-
amine and opioid injection. This lack of knowledge affects
service planning, as countries have no baseline informa-
tion that can be used to assess the effectiveness of efforts
to scale up services.
The overriding limitation of these data is that data
across countries are not collected in a uniform way, with
updated information available for some countries only.
Eleven of the 21 countries provided data by completing
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there were many gaps in terms of programmatic evidence,
simply because such data are not readily available. And,
while the latest progress report on the Global HIV/AIDS
response indicates a dramatic improvement in evidence-
based HIV prevention, even in this report the ‘evidence’
for many countries is either lacking or fragmented. This
data collecting exercise whilst highlighting the lack of spe-
cific HIV-related harm reduction services for PWID in
some countries, offers a benchmark for improving service
coverage in response to emerging injecting trends and
rates of HIV.Conclusion
Despite some limitations, this paper points to the need for
countries, through UNODC offices or other agencies
such European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA), to routinely collect timely data on
IDU and non-IDU trends and related HIV rates using a
standard data collection form and indicators, with similar
time-frames for all countries. PWID remain a high risk
cohort for new HIV transmissions. Standardised and
routine data collection on IDU and HIV would allow policy
makers, researchers and programme planners to monitor
the impact of scaling up HIV treatment (ART) and harm
reduction (NSP/OST) services for PWID. It remains evi-
dent that such services should be widely available to PWID.
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